Patent cliff risk as core da Vinci IP expires 2024-2027, enabling competitors like Medtronic Hugo (launched 2022) and J&J Ottava (expected 2024) to enter with lower-priced alternatives
Reimbursement pressure if CMS or private insurers reduce robotic surgery payments, questioning cost-effectiveness versus laparoscopic alternatives for certain procedures
Technological disruption from single-port systems, flexible robotics, or AI-assisted surgery platforms that bypass Intuitive's installed base advantages
Medtronic Hugo system gaining traction internationally with modular pricing ($500K-1M vs $1.5M+ for Xi) and open architecture attracting cost-conscious hospitals
J&J Ottava leveraging Ethicon's surgical instrument distribution and relationships to bundle robotic systems with existing product lines
Chinese domestic competitors (Microport, Tinavi) capturing local market share with government-supported pricing, limiting international expansion
Minimal financial risk given net cash position and 4.87x current ratio, but large cash balance ($8B+) creates capital allocation pressure for M&A or buybacks that could destroy value
StructuralCompetitiveBalance Sheet
